Pancreatic ductal adenocarcinoma (PDAC) tumors are extremely stiff, and new research shows that this stiffness directly drives tumor growth and chemotherapy resistance. Clinical data from 63 patients using EUS elastography revealed that stiffer tumors (high strain ratio) are associated with advanced tumor stage, more lymph node involvement, and higher rates of metastasis.
The study identified a molecular pathway called the Ca²⁺-DCLK1 mechanotransduction axis. High matrix stiffness activates the PIEZO1 ion channel, allowing calcium to enter cells. This calcium signal, mediated by HPCAL1, turns on DCLK1, which is otherwise inactive in softer environments. DCLK1 then interacts with PIP5K1A, moving it to the cell membrane and activating the PI3K-AKT pathway, promoting cancer cell survival and proliferation.
This biomechanical signaling also drives chemotherapy resistance. Tumors in stiff environments with high DCLK1 are less sensitive to standard treatment, but knocking down DCLK1 or blocking calcium influx restores chemosensitivity. Targeting the calcium/DCLK1 pathway may offer a new approach to treat aggressive pancreatic cancer by interfering with the tumor’s ability to sense and respond to its stiff microenvironment.